Outlook Therapeutics, Inc. (OTLK)
| Market Cap | 156.76M +277.4% |
| Revenue (ttm) | -1.16M |
| Net Income | -61.12M |
| EPS | -0.75 |
| Shares Out | 243.45M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,639,184 |
| Open | 0.6397 |
| Previous Close | 0.6405 |
| Day's Range | 0.6210 - 0.6452 |
| 52-Week Range | 0.1611 - 2.5380 |
| Beta | 0.75 |
| Analysts | Buy |
| Price Target | 4.90 (+660.99%) |
| Earnings Date | Aug 14, 2026 |
About OTLK
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for OTLK stock is "Buy." The 12-month stock price target is $4.9, which is an increase of 660.99% from the latest price.
News
Outlook CFO Lawrence Kenyon to step down, Kevin Lundquist to succeed
Outlook Therapeutics (OTLK) announced the appointment of Kevin Lundquist as CFO, effective September 1. Lundquist most recently served as CFO of CapsoVision (CV). In connection with Lundquist’s appoin...
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
Seasoned finance executive brings more than 20 years of leadership experience across global commercial organizations, including the pharmaceutical and medical technology industries Deep expertise span...
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
Video webcast now available here
Outlook Therapeutics announces common stock, warrants offering
Outlook Therapeutics (OTLK) announced that it has commenced an underwritten public offering of its common stock and accompanying warrants to purchase shares of its common stock. All of the securities…
Outlook Therapeutics $100M Spot Secondary re-offered at 99c
Piper Sandler and BTIG are acting as joint book running managers for the offering.
Outlook Therapeutics 55.6M share Spot Secondary priced at 99c
Piper Sandler and BTIG acted as joint book running managers for the offering.
Outlook Therapeutics reports Q3 EPS (15c), consensus (8c)
Reports Q3 revenue $9,000, consensus $966,670. “FDA approval of LYTENAVA marks a defining moment for Outlook Therapeutics (OTLK) and creates a significant opportunity for the Company in the United Sta...
Outlook Therapeutics Earnings Call Transcript: Q3 2026
FDA approval of LYTENAVA positions it as the only approved ophthalmic bevacizumab for wet AMD in the U.S., targeting a $8.5B retina market. First-year U.S. launch revenue is guided at $50–75M, with peak U.S. sales potential of $500M by 2030, supported by a $55M capital raise.
Outlook Therapeutics Earnings release: Q3 2026
Outlook Therapeutics released its Q3 2026 earnings on August 14, 2026, summarizing the period's financial results.
Outlook Therapeutics Quarterly report: Q3 2026
Outlook Therapeutics has published its Q3 2026 quarterly earnings report on August 14, 2026.
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
The only FDA-approved ophthalmic bevacizumab, LYTENAVA TM , addresses a significant need in the U.S. wet AMD market where bevacizumab is already widely used
Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
ISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a biopharmaceutical company focused on the development and commercialization of LYTE...
Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
ISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a biopharmaceutical company focused on the development and commercialization of LYTE...
Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026
ISELIN, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, ...
Outlook Therapeutics price target raised to $1.60 from 50c at H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Outlook Therapeutics (OTLK) to $1.60 from 50c and keeps a Neutral rating on the shares after the FDA approved…
Outlook Therapeutics upgraded to Buy from Neutral at BTIG
BTIG upgraded Outlook Therapeutics (OTLK) to Buy from Neutral with a $4 price target following FDA approval of LYTENAVA for wet AMD. Outlook Therapeutics has shifted from regulatory uncertainty to…
Outlook Therapeutics upgraded to Buy from Neutral at BTIG
BTIG upgraded Outlook Therapeutics (OTLK) to Buy from Neutral with a $4 price target
Outlook Therapeutics Inc trading resumes
15:00 EDT Outlook Therapeutics (OTLK) Inc trading resumes
US FDA approves Outlook Therapeutics' eye disease drug
Outlook Therapeutics said on Friday the U.S. Food and Drug Administration has approved its drug for a type of eye disease that can cause severe vision loss.
Outlook Therapeutics announces FDA approval of Lytenava for wet AMD
Outlook Therapeutics (OTLK) announced that the Food and Drug Administration has approved Lytenava for the treatment of neovascular age-related macular degeneration, commonly known as wet AMD. “The app...
Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD
Landmark FDA Approval Is an Important Milestone in Retina Care, Bringing Patients and Physicians an Ophthalmic Bevacizumab Developed Specifically for the Eye Following Years of Rigorous Clinical and R...
Outlook Therapeutics Inc trading halted, news pending
13:34 EDT Outlook Therapeutics (OTLK) Inc trading halted, news pending
Outlook Therapeutics registers to sell 17.26M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 17.26M shares of common stock. The company is not selling any…
Outlook Therapeutics Registration statement: Registration filing
Outlook Therapeutics filed a registration statement on July 17, 2026, providing details about a securities offering with the SEC.
Outlook Therapeutics Proxy statement: Proxy filing
Outlook Therapeutics filed a proxy statement on July 10, 2026, providing details for shareholder voting and corporate governance matters.